Seems like the leading possible replacements for FDA chief will be pro cbd.
“CBD has negligible potential for abuse,” wrote Dr. Brett Giroir, the assistant secretary for health in the U.S. Health and Human Services Department, FDA’s parent agency.
Giroir noted that CBD doesn’t meet the description of even the least-restrictive class of controlled substances, Schedule 5.
Market Data 
Markets 
AI
